Loading...
XMAD
ECR
Market cap358mUSD
Sep 10, Last price  
3.49EUR
Name

Ercros SA

Chart & performance

D1W1MN
XMAD:ECR chart
P/E
—
P/S
0.51
EPS
—
Vol. 1Y
—
Shs. 5Y
-2.28%
Rev. 5Y
1.96%
Div Yld LY
2.75%
Div Yld TTM
—
Revenues
627m
-6.08%
721,000,000844,650,000866,490,000569,810,000609,280,000686,040,000639,540,000624,970,000603,670,000618,270,000602,540,000685,970,000671,940,000669,782,000568,797,000772,317,000998,532,000725,294,000667,415,000626,815,000
Net income
-54m
L+359.68%
4,850,000-3,276,000,000-203,020,000-49,480,000-12,380,000-810,000-12,130,000-3,750,000-6,290,0007,240,00045,160,00044,582,00044,876,00031,043,0006,257,00043,297,00062,989,00027,585,000-11,657,000-53,585,000
CFO
49m
+417.01%
-14,540,00031,620,000-680,000,00040,910,000-10,580,00011,520,00019,170,00023,860,00028,050,00014,000,00038,950,00043,813,00044,876,00059,431,00074,591,00060,324,00062,989,00051,140,0009,514,00049,188,000
Dividend
Jul 08, 20240.096 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.

Key people

Antonio Zabalza Marti
Executive Chairman of the Board, Chief Executive Officer · since 1996
Pedro Rodriguez Sanchez
Chief Financial and Economic Officer · since 2006
Agustin Franco Blasco
Chief Operating Officer · since 2017
Xavier Alvarez Garcia
Director - Internal Audit Service · since 2016
Non-Member Secretary of the Board · since 2016
Joan Casas Galofre
Proprietary Director · since 2020
Laureano Roldan Aguilar
Other External Director · since 1996
Eduardo Sanchez Morrondo
Other External Director · since 2016
Carme Moragues Josa
Lead Independent Director · since 2017
Maria Lourdes Vega Fernandez
Independent Director · since 2016
IPO date
Sep 17, 1990
Employees
1,343
Domiciled in
ES
Incorporated in
ES
Legal address
Avda. Diagonal 593-595 5" planta (Recepción)
Barcelona 08014
ES
Headquarters
Avda. Diagonal 593-595 10ª planta (Asesoría Jurídica)
Barcelona 08014
ES

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT